title: High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.
authors.forename: Denise A
authors.initials: DA
authors.lastname: McKeown
authors.forename: Melanie
authors.initials: M
authors.lastname: Rosenvinge
authors.forename: Sheila
authors.initials: S
authors.lastname: Donaghy
authors.forename: Mike
authors.initials: M
authors.lastname: Sharland
authors.forename: David W
authors.initials: DW
authors.lastname: Holt
authors.forename: Ian
authors.initials: I
authors.lastname: Cormack
authors.forename: Phillip
authors.initials: P
authors.lastname: Hay
authors.forename: S Tariq
authors.initials: ST
authors.lastname: Sadiq
mesh_terms: D000328:Adult; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D010920:Placenta / Q000098:blood supply / Q000187:drug effects*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D011760:Pyrrolidinones / Q000097:blood / Q000493:pharmacokinetics*; D000068898:Raltegravir Potassium
chemical_list: D011760:Pyrrolidinones; D000068898:Raltegravir Potassium